本文選題：雷替曲塞 + 晚期結(jié)直腸癌　； 參考：《鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版)》2017年03期

【摘要】：目的:觀察雷替曲塞聯(lián)合奧沙利鉑二線治療晚期結(jié)直腸癌的臨床療效及安全性。方法:收集鄭州大學(xué)第一附屬醫(yī)院收治的經(jīng)一線治療失敗的晚期結(jié)直腸癌患者57例,采用隨機(jī)數(shù)字表法分為2組。28例采用TOMOX方案治療,29例采用FOLFOX4方案治療,評(píng)價(jià)2組療效及不良反應(yīng)。結(jié)果:TOMOX組和FOLFOX4組有效率分別為14.3%(4/28)和10.3%(3/29),疾病控制率分別為78.6%(22/28)和82.7%(24/29)(P0.05)。TOMOX組的無(wú)疾病進(jìn)展生存期(PFS)為8.30個(gè)月,FOLFOX4組的PFS為8.10個(gè)月;TOMOX組的總生存期(OS)為15.40個(gè)月,FOLFOX4組的OS為14.10個(gè)月(P0.05)。TOMOX組中性粒細(xì)胞減少及心臟毒性的發(fā)生率低于FOLFOX4組,而TOMOX組轉(zhuǎn)氨酶升高的發(fā)生率較FOLFOX4組高(P0.05),但多為Ⅰ~Ⅱ級(jí),可耐受。結(jié)論:雷替曲塞聯(lián)合奧沙利鉑二線治療晚期結(jié)直腸癌的療效確切,且具有不良反應(yīng)輕、易耐受等特點(diǎn)。
[Abstract]:Objective: To observe the clinical efficacy and safety of retrexed and oxaliplatin in the treatment of advanced colorectal cancer. Methods: 57 patients with advanced colorectal cancer who were treated in the First Affiliated Hospital of Zhengzhou University were collected and divided into 2 groups of.28 cases by random digital table method and 29 cases were treated with FOLFOX4 scheme. Results: the efficacy and adverse effects of 2 groups were evaluated. Results: the effective rates of group TOMOX and group FOLFOX4 were 14.3% (4/28) and 10.3% (3/29) respectively. The disease control rate was 78.6% (22/28) and 82.7% (24/29) (P0.05).TOMOX group was 8.30 months, and FOLFOX4 PFS was 8.10 months; the total survival period of the TOMOX group was 15.40 months. The incidence of neutrophils and cardiotoxicity in the 4 group of OS groups was lower than that in the group FOLFOX4, but the incidence of elevated transaminase in the TOMOX group was higher than that in the FOLFOX4 group (P0.05), but more than the class I (P0.05), but it was more tolerable. Conclusion: retrexed combined with oxaliplatin second line treatment for advanced colorectal cancer is effective and has adverse reaction. It should be light and easy to tolerate.
【作者單位】： 鄭州大學(xué)第一附屬醫(yī)院腫瘤科;
【基金】：河南省教育廳科學(xué)技術(shù)研究重點(diǎn)項(xiàng)目13A320638
【分類號(hào)】：R735.34

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 紀(jì)媛媛;李軍擴(kuò);洪永貴;;雷替曲塞單藥治療晚期結(jié)直腸癌療效觀察[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2013年25期

2 煥然;;晚期結(jié)直腸癌的治療[J];國(guó)外醫(yī)學(xué)情報(bào);1999年02期

3 郁寶銘;晚期結(jié)直腸癌的綜合治療[J];中國(guó)實(shí)用外科雜志;2000年10期

4 張文,許立功;晚期結(jié)直腸癌的化療進(jìn)展[J];中國(guó)癌癥雜志;2004年04期

5 趙新漢,馬欣;晚期結(jié)直腸癌時(shí)間化療研究進(jìn)展[J];現(xiàn)代腫瘤醫(yī)學(xué);2005年04期

6 古曉東;裴毅;;晚期結(jié)直腸癌的化療進(jìn)展[J];國(guó)際腫瘤學(xué)雜志;2006年09期

7 費(fèi)小非;湯致強(qiáng);;晚期結(jié)直腸癌三種化療方案的成本-效果分析[J];中國(guó)新藥雜志;2006年08期

8 肖慶成;吳成中;;晚期結(jié)直腸癌的綜合治療(附32例報(bào)告)[J];實(shí)用臨床醫(yī)學(xué);2007年04期

9 劉琳;劉杰;王哲海;宋寶;郭s，

本文編號(hào)：1905378